Core Viewpoint - The stock of HAPO Pharmaceutical (02142) has increased by over 3%, currently trading at HKD 12.67 with a transaction volume of HKD 30.48 million, following the announcement of a successful project approval related to pancreatic cancer research [1] Group 1: Project Approval - The "Research on the Pathogenesis and Clinical Precision Diagnosis and Treatment New Paradigm of Pancreatic Cancer" project, led by Shanghai Changzheng Hospital and involving HAPO Pharmaceutical, has been officially approved under the National Science and Technology Innovation 2030 major special project for 2025 [1] Group 2: Company Focus and Collaborations - HAPO Pharmaceutical is dedicated to the development of innovative antibody therapies in the fields of oncology and immune diseases, utilizing its fully human transgenic mouse platform, Harbour Mice, as a technological foundation [1] - The company has established deep collaborations with several global pharmaceutical giants, including AstraZeneca, Pfizer, Bristol-Myers Squibb, Otsuka Pharmaceutical, AbbVie, and Moderna, which reflects its recognized technical strength [1] Group 3: Pipeline Development - HAPO Pharmaceutical has over 20 product pipelines, including bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs) [1] - Innovative therapies targeting CLDN18.2 and LIFR have entered clinical or application stages, adding diversified momentum to the treatment matrix for pancreatic cancer [1]
和铂医药-B涨超3% 与长海医院联合申报的攻坚胰腺癌项目获国家科技创新重大专项立项